pharmacology
What’s being done for T2DM care across Africa?
Open access · cc by · source: Europe PMC
With ~19M adults with diabetes (→47M by 2045 if unchecked), African systems are expanding diagnosis/adherence programs—but major gaps remain, especially with HIV/TB co-morbidity.
Key findings
Many countries are launching detection, monitoring, and adherence programs amid rising obesity/urbanization drivers; co-morbid HIV/TB complicates care; authors judge efforts still insufficient for the growing burden.
Methodology
Synthesized publications and senior government/academic input on national initiatives for identification, access, lifestyle change, medicines adherence, and infectious co-morbidities.
Limitations
Not a single-country RCT; impact of many initiatives is too early to quantify fully.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
National STEPS data can show rising awareness while control stays low.
Iranian STEPS analyses found diabetes prevalence and awareness climbing, treatment peaking then dipping, and glycemic control remaining low—illustrating cascade leakage after detection.
Scope note — multi-country program review — not the same national cascade measurement
Limits the claim's scope: a different population, assay, or outcome.
Many countries run T2DM detection/adherence programs, but authors still judge them insufficient for rising burden.
A review of ongoing T2DM care activities highlights detection, monitoring, and adherence efforts amid obesity/urbanization drivers and HIV/TB co-morbidity, while arguing current efforts under-match need.
Evidence for the claim as stated.
Awareness up, control still low in national survey vs Many programs exist but judged insufficient vs App-level self-management support in T1D
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Awareness up, control still low in national survey vs Many programs exist but judged insufficient vs App-level self-management support in T1D
Related papers in this topic
Same topic cluster — not a recommendation engine.